Founded by a world-renowned group of leading physicians and researcher scientists TheraCell is an early revenue stage regenerative medicine company developing the next generation of advanced technologies for tissue repair. Amongst these is a family of best-in-class patent pending allograft products licensed to one of the largest US tissue banks. These include our demineralized bone fiber (DBF)™ line of allograft putties and strips, and a unique DBM infused cancellous sponge. The company technology also includes a patented platform of synthetic oxygen carrier technologies for enhancing bone growth in conjunction with DBM’s, putties, cell containing products, or as a component of a non-DBM synthetic bone void fillers. A critical blocking patent for this technology was issued to Theracell by the USPTO in 2014. The oxygenation technology has been tested in a number of pre-clinical trials using several DBM's on the market today, as well as stem cells. In all prior studies our oxygenation technology has been shown to enhance healthy and high quality bone formation in animal tests. In these studies the company obtained statistically significant evidence of improved bone quality and growth.
